RecruitingNCT07412756
Brenipatide or placebo added to usual care to study depression relapse
About this title
Read the official source — NCT07412756This study evaluates the safety and effectiveness of Brenipatide for people with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Brenipatide for people with depression.
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- Moorpark and 180 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 9, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 1,000
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07412756
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)
Recruitment & locations
RecruitingMoorpark, United States · Orange, United States · New Haven, United States
153 more locations
- Hollywood, United States
- Maitland, United States
- Miami Gardens, United States
- Miami Lakes, United States
- Naples, United States
- Orange City, United States
- Orlando, United States
- Tampa, United States
- Decatur, United States
- Indianapolis, United States
- Waterloo, United States
- Baltimore, United States
- Boston, United States
- Foxborough, United States
- Watertown, United States
- Troy, United States
- St Louis, United States
- Las Vegas, United States
- New York, United States
- Portland, United States
- Philadelphia, United States
- West Chester, United States
- Sioux Falls, United States
- DeSoto, United States
- Fort Worth, United States
- Shavano Park, United States
- Clinton, United States
- Fairfax, United States
- Bellevue, United States
- Carlton, Australia
- Elizabeth Vale, Australia
- Geelong, Australia
- Melbourne, Australia
- Northcote, Australia
- Toowoomba, Australia
- Westmead, Australia
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Maringá, Brazil
- Marília, Brazil
- Natal, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Valinhos, Brazil
- Calgary, Canada
- Hamilton, Canada
- Kelowna, Canada
- Lévis, Canada
- Montreal, Canada
- Ottawa, Canada
- Québec, Canada
- Richmond, Canada
- Sarnia, Canada
- Sherbrooke, Canada
- Surrey, Canada
- Toronto, Canada
- Beijing, China
- Changsha, China
- Chaohu, China
- Chengdu, China
- Guangzhou, China
- Haidian District, China
- Hefei, China
- Huzhou, China
- Jining, China
- Nanchang, China
- Ningbo, China
- Shanghai, China
- Shijiazhuang, China
- Suzhou, China
- Tianjin, China
- Wuhan, China
- Wuxi, China
- Xi'an, China
- Xianyang, China
- Zhenjiang, China
- Zhumadian, China
- Aachen, Germany
- Berlin, Germany
- Bielefeld, Germany
- Chemnitz, Germany
- Mainz, Germany
- Mannheim, Germany
- Schwerin, Germany
- Siegen, Germany
- Argos, Greece
- Athens, Greece
- Chaïdári, Greece
- Stavroupoli, Greece
- Thessaloniki, Greece
- Tripoli, Greece
- Arakawa City, Japan
- Chikugo, Japan
- Chiyoda City, Japan
- Fukuoka, Japan
- Fukushima, Japan
- Ginowan, Japan
- Hiratsuka, Japan
- Karatsu, Japan
- Kawasaki, Japan
- Kōtō City, Japan
- Kumamoto, Japan
- Kure, Japan
- Kurume, Japan
- Meguro-ku, Japan
- Nagasaki, Japan
- Sagamihara, Japan
- Setagaya City, Japan
- Shibuya-ku, Japan
- Shirakawa, Japan
- Tokyo, Japan
- Yamagata, Japan
- Yokohama, Japan
- Yokosuka, Japan
- Chihuahua City, Mexico
- Guadalajara, Mexico
- Mazatlán, Mexico
- Mexico City, Mexico
- Mérida, Mexico
- Morelia, Mexico
- Veracruz, Mexico
- Bialystok, Poland
- Bielsko-Biala, Poland
- Gdansk, Poland
- Krakow, Poland
- Poznan, Poland
- Szczecin, Poland
- Wroclaw, Poland
- Zabrze, Poland
- Bayamón, Puerto Rico
- Ansan-si, South Korea
- Gwangju, South Korea
- Jeju City, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Salamanca, Spain
- Zamora, Spain
- Keelung, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Edinburgh, United Kingdom
- Exeter, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Nottingham, United Kingdom
- Oxford, United Kingdom
- Penzance, United Kingdom
- Rotherham, United Kingdom
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Brenipatide for people with depression.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Brenipatide and Placebo.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as recruiting.
